These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33991836)

  • 1. Discovery of pseudolaric acid A as a new Hsp90 inhibitor uncovers its potential anticancer mechanism.
    Liu J; Wu XD; Li W; Yuan Z; Yang K; Zhao QS
    Bioorg Chem; 2021 Jul; 112():104963. PubMed ID: 33991836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel HSP90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells.
    Wei Q; Ning JY; Dai X; Gao YD; Su L; Zhao BX; Miao JY
    Eur J Med Chem; 2018 Feb; 145():551-558. PubMed ID: 29339250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of vibsanin A analog as a novel HSP90 inhibitor.
    Miura K; Matsuki W; Ogura A; Takao KI; Simizu S
    Bioorg Med Chem; 2020 Jan; 28(2):115253. PubMed ID: 31859027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 18β-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug resistance.
    Jin L; Huang R; Huang X; Zhang B; Ji M; Wang H
    Bioorg Med Chem; 2018 May; 26(8):1759-1775. PubMed ID: 29486954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinazoline Based HSP90 Inhibitors: Synthesis, Modeling Study and ADME Calculations Towards Breast Cancer Targeting.
    El-Shafey HW; Gomaa RM; El-Messery SM; Goda FE
    Bioorg Med Chem Lett; 2020 Aug; 30(15):127281. PubMed ID: 32527460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel celastrol-triazole derivatives with Hsp90-Cdc37 disruption to induce tumor cell apoptosis.
    Li N; Chen C; Zhu H; Shi Z; Sun J; Chen L
    Bioorg Chem; 2021 Jun; 111():104867. PubMed ID: 33845380
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
    Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
    Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-((1-Phenyl-1H-1,2,3-triazol-4-yl)methyl)-2-azabicyclo[3.2.1]octan-3-one derivatives: Simplification and modification of aconitine scaffold for the discovery of novel anticancer agents.
    Zhang Y; Zhang TJ; Li XY; Liang JW; Tu S; Xu HL; Xue WH; Qian XH; Zhang ZH; Zhang X; Meng FH
    Eur J Med Chem; 2021 Jan; 210():112988. PubMed ID: 33189438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of N-pyridoyl-Δ
    Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and anticancer evaluation of novel andrographolide derivatives bearing an α,β-unsaturated ketone moiety.
    Cai W; Li J; Chen C; Wu J; Li J; Xue X
    Bioorg Chem; 2021 Jul; 112():104941. PubMed ID: 33940445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Product Kongensin A is a Non-Canonical HSP90 Inhibitor that Blocks RIP3-dependent Necroptosis.
    Li D; Li C; Li L; Chen S; Wang L; Li Q; Wang X; Lei X; Shen Z
    Cell Chem Biol; 2016 Feb; 23(2):257-266. PubMed ID: 27028885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anticancer Hsp90 inhibitor disubstituted pyrazolyl 2-aminopyrimidine compound 7t induces cell cycle arrest and apoptosis via mitochondrial pathway in MCF-7 cells.
    Mettu A; Talla V; Naikal SJP
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127470. PubMed ID: 32795627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities.
    Li N; Xu M; Bao N; Shi W; Li Q; Zhang X; Sun J; Chen L
    Eur J Med Chem; 2018 Dec; 160():1-8. PubMed ID: 30316059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New modification strategy of matrine as Hsp90 inhibitors based on its specific L conformation for cancer treatment.
    Xu Y; Jing D; Zhao D; Wu Y; Xing L; Ur Rashid H; Wang H; Wang L; Cao H
    Bioorg Med Chem; 2020 Feb; 28(4):115305. PubMed ID: 31928863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel heat shock protein (Hsp90) inhibitors based on luminespib with potent antitumor activity.
    Jung J; Kwon J; Hong S; Moon AN; Jeong J; Kwon S; Kim JA; Lee M; Lee H; Lee JH; Lee J
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127165. PubMed ID: 32305165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of BP3 as an efficacious proteolysis targeting chimera (PROTAC) degrader of HSP90 for treating breast cancer.
    Liu Q; Tu G; Hu Y; Jiang Q; Liu J; Lin S; Yu Z; Li G; Wu X; Tang Y; Huang X; Xu J; Liu Y; Wu L
    Eur J Med Chem; 2022 Jan; 228():114013. PubMed ID: 34864330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization and biological evaluation of celastrol derivatives as Hsp90-Cdc37 interaction disruptors with improved druglike properties.
    Jiang F; Wang HJ; Bao QC; Wang L; Jin YH; Zhang Q; Jiang D; You QD; Xu XL
    Bioorg Med Chem; 2016 Nov; 24(21):5431-5439. PubMed ID: 27647369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
    Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
    Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a simplified deguelin analog as an HSP90 C-terminal inhibitor for HER2-positive breast cancer.
    Nguyen CT; Thanh La M; Ann J; Nam G; Park HJ; Min Park J; Kim YJ; Young Kim J; Hong Seo J; Lee J
    Bioorg Med Chem Lett; 2021 Aug; 45():128134. PubMed ID: 34044120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the Hsp90 Inhibitors Containing 4-(2,4-Dihydroxyphenyl)-1,2,3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells.
    Kazlauskas E; Brukstus A; Petrikas H; Petrikaite V; Cikotiene I; Matulis D
    Anticancer Agents Med Chem; 2017 Nov; 17(11):1593-1603. PubMed ID: 28270068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.